Article
Dose-dependent improvements in learning and memory deficits in APPPS1-21 transgenic mice treated with the orally active Aβ toxicity inhibitor SEN1500.
Neuropharmacology - 1 Dec 2013
Lo Adrian C, Tesseur Ina, Scopes David I C, Nerou Edmund, Callaerts-Vegh Zsuzsanna, Vermaercke Ben, Treherne J Mark, De Strooper Bart, D'Hooge Rudi
Abstract excerpt
In the Alzheimer's disease (AD) brain, accumulation of Aβ1-42 peptides is suggested to initiate a cascade of pathological events. To date, no treatments are available that can reverse or delay AD-related symptoms in patients. In the current study, we introduce a new Aβ toxicity inhibitor, SEN1500, which in addition to its block effect on Aβ1-42 toxicity in synaptophysin assays, can be administered orally and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.